These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 19479708)

  • 41. [RETROSPECTIVE DATA ANALYSIS OF THE PATIENTS WITH INFLAMMATORY JOINT DISEASES TREATED WITH GOLIMUMAB IN CROATIA].
    Anić B; Babić-Naglić Ð; Grazio S; Kehler T; Kaliterna DM; Radoncić KM; Morović-Vergles J; Novak S; Prus V; Vlak T; Baresić M
    Reumatizam; 2015; 62(1):12-9. PubMed ID: 27024887
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Methotrexate and anti-tumor necrosis factor treatment improves endothelial function in patients with inflammatory arthritis.
    Deyab G; Hokstad I; Whist JE; Smastuen MC; Agewall S; Lyberg T; Ronda N; Mikkelsen K; Hjeltnes G; Hollan I
    Arthritis Res Ther; 2017 Oct; 19(1):232. PubMed ID: 29041979
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice.
    Kievit W; Fransen J; Oerlemans AJ; Kuper HH; van der Laar MA; de Rooij DJ; De Gendt CM; Ronday KH; Jansen TL; van Oijen PC; Brus HL; Adang EM; van Riel PL
    Ann Rheum Dis; 2007 Nov; 66(11):1473-8. PubMed ID: 17426065
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anti cytokine therapy in chronic inflammatory arthritis.
    Thompson C; Davies R; Choy E
    Cytokine; 2016 Oct; 86():92-99. PubMed ID: 27497159
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anti-tumour necrosis factor treatment increases circulating T helper type 17 cells similarly in different types of inflammatory arthritis.
    Hull DN; Williams RO; Pathan E; Alzabin S; Abraham S; Taylor PC
    Clin Exp Immunol; 2015 Sep; 181(3):401-6. PubMed ID: 25766640
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Thalassemic trait prevalence in patients affected by psoriatic arthritis in anti-TNF treatment.
    Atteno M; Costa L; Vitiello M; Caso F; Sarnelli G; Del Puente A; Scarpa R
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S20-2. PubMed ID: 25381968
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis.
    Girolomoni G; Altomare G; Ayala F; Berardesca E; Calzavara-Pinton P; Chimenti S; Peserico A; Puglisi Guerra A; Vena GA
    Immunopharmacol Immunotoxicol; 2012 Aug; 34(4):548-60. PubMed ID: 22296031
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden.
    Hellgren K; Smedby KE; Backlin C; Sundstrom C; Feltelius N; Eriksson JK; Baecklund E; Askling J
    Arthritis Rheumatol; 2014 May; 66(5):1282-90. PubMed ID: 24782185
    [TBL] [Abstract][Full Text] [Related]  

  • 49. "Are there any evidences for using the intra-articular TNF-α blockade in resistant arthritis?".
    Fiocco U; Punzi L
    Joint Bone Spine; 2011 Jul; 78(4):331-4. PubMed ID: 21353617
    [No Abstract]   [Full Text] [Related]  

  • 50. Effects of anti-TNF therapy on glucose metabolism in patients with ankylosing spondylitis, psoriatic arthritis or juvenile idiopathic arthritis.
    da Silva BS; Bonfá E; de Moraes JC; Saad CG; Ribeiro AC; Gonçalves CR; de Carvalho JF
    Biologicals; 2010 Sep; 38(5):567-9. PubMed ID: 20638299
    [TBL] [Abstract][Full Text] [Related]  

  • 51. MonitorNet: the Italian multi-centre observational study aimed at estimating the risk/benefit profile of biologic agents in real-world rheumatology practice.
    Sfriso P; Salaffi F; Montecucco CM; Bombardieri S; Todesco S
    Reumatismo; 2009; 61(2):132-9. PubMed ID: 19633800
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Golimumab (simponi) for inflammatory arthritis.
    Med Lett Drugs Ther; 2009 Jul; 51(1316):55-6. PubMed ID: 19590489
    [No Abstract]   [Full Text] [Related]  

  • 53. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
    Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
    Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of treatment with TNF antagonists on total cholesterol in patients with ankylosing spondylitis and psoriatic arthritis.
    Maneiro JR; Souto A; Gomez-Reino JJ
    Clin Rheumatol; 2017 May; 36(5):1167-1172. PubMed ID: 28108800
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.
    Cepeda EJ; Williams FM; Ishimori ML; Weisman MH; Reveille JD
    Ann Rheum Dis; 2008 May; 67(5):710-2. PubMed ID: 18079191
    [TBL] [Abstract][Full Text] [Related]  

  • 56. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.
    Tobin AM; Kirby B
    BioDrugs; 2005; 19(1):47-57. PubMed ID: 15691217
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ten-year drug survival of anti-TNF agents in the treatment of inflammatory arthritides.
    Biggioggero M; Favalli EG
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S38-41. PubMed ID: 25381973
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anti-TNF Therapy and the Risk of Malignancies and Infections in Inflammatory Rheumatic Diseases - Our Experience.
    Pap M; Sapina I; Laktašić Žerjavić N; Žagar I; Kovač Durmiš K; Kalebota N; Kovačević P; Caktaš IL; Dekleva V; Birkić D; Kolar Mitrović H; Perić P
    Psychiatr Danub; 2021; 33(Suppl 4):625-631. PubMed ID: 34718291
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Golimumab - a new tool in the armoury against inflammatory arthritis.
    Ash Z; Emery P
    Ann Med; 2011 Mar; 43(2):133-41. PubMed ID: 21244218
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period.
    Conti F; Ceccarelli F; Marocchi E; Magrini L; Spinelli FR; Spadaro A; Scrivo R; Valesini G
    Ann Rheum Dis; 2007 Oct; 66(10):1393-7. PubMed ID: 17613555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.